Social Media in the Pharmaceutical Industry

SMi Group22 - 23 January 2018, London, UK.
Social media is the perfect channel for pharmaceutical companies to educate, market, listen and connect with customers, patients and physicians. How the pharmaceutical industry utilize social media is particularly complex as regulators such as the FDA have not yet written the rules about how pharmaceuticals can engage with potential customers and patients.

Join SMi's 10th Annual Social Media in the Pharmaceutical Industry Conference to learn the best way your company can benefit from social media. Hear from industry experts on how to leverage social media platforms to develop a robust digital strategy and discuss the latest challenges and techniques in the field of 'social pharma'.

How Will You Benefit?

Network and learn from leading professionals such as:
  • Emma Sutcliffe, Director, Patient Engagement & Innovation, NexGen Healthcare
  • Tughan Demirbilek, Strategy & Operations Director, Bristol-Myers Squibb
  • Marcel Gmünder, Global Head, Digital Health Group, Roche Diabetes Care
  • Elodie Douangmanivanh, Head of Digital Services, MSD
  • Sebastian Soithongsuk, Global Content Manager Digital Comms, GSK
  • Aslihan Unal, Digital Strategy Group Manager, Janssen
  • Hervé Dumas, Patients’ Technology Solutions Lead, UCB
  • Sarah Holiday, Social Media Strategy Lead, Pfizer

Some Featured Highlights will include:

  • Hear how Janssen create powerful pharmaceutical social media strategies enabling patient engagement.
  • Learn how to build integrated, impactful social media strategies with Pfizer.
  • Discuss the potential of wearable technologies creating behavioural changes for patients with UCB.
  • Discover with GSK how to make your social media content less "promotional" and more about storytelling.
  • Examine how Bristol Myers-Squibb create an excellent digital strategy whilst engaging patients.

For further information and to register, please visit:
http://www.social-media-pharma.com/wpn

Early-Bird Rates

  • Book by 31st October and save £200
  • Book by 30th November and save £100

About SMi Group
The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

SK bioscience and GSK start Phase 3 trial of adjuv…

SK bioscience (SK) and GlaxoSmithKline plc (GSK) today announced the initiation of a Phase 3 clinical study of SK's COVID-19 vaccine candidate, GBP510, in combination wit...

Blood vessels produce growth factor that promotes …

Blood vessels supply tumors with nutrients and, on the other hand, enable cancer cells to spread throughout the body. The settlement of circulating tumor cells in a dista...

No serious health effects linked to mRNA COVID-19 …

Federal and Kaiser Permanente researchers combing the health records of 6.2 million patients found no serious health effects that could be linked to the 2 mRNA COVID-19 v...

First-in-human clinical trial for a vaccine to tre…

The first patients have been enrolled in a phase 1 randomized placebo-controlled clinical trial to study a therapeutic vaccine for opioid use disorder developed by resear...

New study examines 'Achilles heel' of cancer tumou…

Researchers at the University of British Columbia's faculty of medicine and BC Cancer Research Institute have uncovered a weakness in a key enzyme that solid tumour cance...

AI algorithm solves structural biology challenges

Determining the 3D shapes of biological molecules is one of the hardest problems in modern biology and medical discovery. Companies and research institutions often spend ...

A drug costing less than €2 a day helps in the tre…

Metoprolol, a drug widely used to treat cardiovascular disease, is beneficial when administered to COVID-19patients. This is the finding of a study by investigators at th...

Sandoz strengthens pipeline by entering into agree…

Sandoz, a Novartis division, today announced that it has entered into a commercialization agreement with Bio-Thera Solutions, Ltd. for biosimilar bevacizumab (BAT1706). B...

Pfizer and BioNTech submit a variation to EMA with…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that they submitted a variation to the European Medicines Agency (EMA) requesting to update the Condition...

Rheumatoid arthritis treated with implanted cells …

With a goal of developing rheumatoid arthritis therapies with minimal side effects, researchers at Washington University School of Medicine in St. Louis have genetically ...

One in three Americans had COVID-19 by the end of …

A new study published in the journal Nature estimates that 103 million Americans, or 31 percent of the U.S. population, had been infected with SARS-CoV-2 by the end of 20...

NIH scientists build a cellular blueprint of multi…

Chronic lesions with inflamed rims, or "smoldering" plaques, in the brains of people with multiple sclerosis (MS) have been linked to more aggressive and disabling forms ...